Drug Trial Radar · NCT03719443
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Oct 9, 2018
Primary completion
Aug 10, 2019
Study completion Aug 10, 2019
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Oct 25, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase 1, randomized, placebo-controlled, double-blind, single ascending dose study of IV VIS649 in healthy subjects. VIS649 is a monoclonal immunoglobulin G2 (IgG2) antibody targeting the B-cell growth factor APRILL. The study will enroll up to 45 subjects and will be conducted in up to 5 sequential dosing cohorts at four different dose levels, enrolling 9 subjects per cohort. Subjects will be randomized to VIS649 or placebo in a ratio of 7:2 (7 active, 2 placebo). Safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from the initial cohorts will be assessed.
Conditions
- Immunoglobulin A Nephropathy
- IgAN - IgA Nephropathy
- IgA Nephropathy
Interventions
VIS649Biological
Single IV dose of study product on Day 1 of study
PlaceboBiological
Singe IV dose of placebo administered via IV on Day 1 of study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Summary of Treatment Emergent Adverse EventsTime frame: Baseline to day 112
Locations
1 site in 1 country. Site status is shown where the registry gives one.
California Clinical Trials Medical Group
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.